Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Patanè, Monica ^a   Porrati, Paola ^a   Bottega, Elisa ^a   Morosini, Sara ^b   Cantini, Gabriele ^b   Girgenti, Vita ^a   Rizzo, Ambra ^a   Eoli, Marica ^a   Pollo, Bianca ^a   Sciacca, Francesca L ^a   Pellegatta, Serena ^a,b   Finocchiaro, Gaetano ^a,b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b Department of Experimental Oncology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TRANSCRIPTION FACTOR RELA;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE DELETION; GENETIC ANALYSIS; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; X CHROMOSOME;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, X; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; I-KAPPA B PROTEINS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84889817926     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-160     Document Type: Article

References (42)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005, 109:93-108. 10.1007/s00401-005-0991-y, 15685439.
2. Kotliarova S, Fine HA. Snapshot: glioblastoma multiforme. Cancer Cell 2012, 21:710-710. e1, 10.1016/j.ccr.2012.04.031, 22624719.
3. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173. 10.1016/j.ccr.2006.02.019, 16530701.
4. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. 10.1016/j.ccr.2009.12.020, 2818769, 20129251.
5. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012, 26:756-784. 10.1101/gad.187922.112, 3337451, 22508724.
6. Bonavia R, Inda MM, Vandenberg S, Cheng S-Y, Nagane M, Hadwiger P, Tan P, Sah DWY, Cavenee WK, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene 2011, 31:4054-4066. 3537826, 22139077.
7. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 2011, 1:524-538. 10.1158/2159-8290.CD-11-0124, 3229221, 22145100.
8. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung M-C, Lin X. CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res 2011, 71:2183-2192. 10.1158/0008-5472.CAN-10-3626, 3059846, 21406399.
9. Viatour P, Merville M-P, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52. 10.1016/j.tibs.2004.11.009, 15653325.
10. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942, 17072330.
11. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL, Galli R. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010, 70:7500-7513. 10.1158/0008-5472.CAN-10-2353, 20858720.
12. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997, 272:2927-2935. 10.1074/jbc.272.5.2927, 9006938.
13. Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 2012, 25:774-779. 10.1097/WCO.0b013e328359b0bc, 23007009.
14. Fan Q-W, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma. Cancer Cell 2013, 24:438-449. 10.1016/j.ccr.2013.09.004, 24135280.
15. Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, Gonzalez-Darder J, Quilis V, Monleon D, Celda B, Cerdá-Nicolas M. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Mod Pathol 2010, 23:856-865. 10.1038/modpathol.2010.62, 20305620.
16. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97:8542-8547. 10.1073/pnas.97.15.8542, 26984, 10900013.
17. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z. EGFR-induced and PKCε{lunate} monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 2012, 48:771-784. 10.1016/j.molcel.2012.09.028, 3526114, 23123196.
18. Kapoor GS, Zhan Y, Johnson GR, O'Rourke DM. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 2004, 24:823-836. 10.1128/MCB.24.2.823-836.2004, 343802, 14701753.
19. Alvarez AA, Sc B, Renfrow JJ, Chandler JP, Yu ILY, Sc M, Carro MS, Ph D, Dai F, Tagge MJ, Ferrarese R, Bredel C, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Iv GRH, Bredel M, Scholtens DM, Yadav AK, Phillips HS, Lukac PJ, Robe PA, Sikic BI, Aldape KD, Chakravarti A, Harsh GR. NFKBIA deletion in glioblastomas. N Engl J Med 2011, 364:627-637. 10.1056/NEJMoa1006312, 3652611, 21175304.
20. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, Sanada M, Jauch A, Dugas M, Black KL, Koeffler HP. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 2009, 7:665-677. 10.1158/1541-7786.MCR-08-0270, 19435819.
21. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron 2008, 58:832-846. 10.1016/j.neuron.2008.05.031, 18579075.
22. Tunici P, Bissola L, Lualdi E, Pollo B, Cajola L, Broggi G, Sozzi G, Finocchiaro G. Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer 2004, 3:25. 10.1186/1476-4598-3-25, 524518, 15469606.
23. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403. 10.1016/j.ccr.2006.03.030, 16697959.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
25. Inda M-M, Bonavia R, Mukasa A, Narita Y, Sah DWY, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010, 24:1731-1745. 10.1101/gad.1890510, 2922502, 20713517.
26. Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 2012, 18:1901-1913. 10.1158/1078-0432.CCR-11-3084, 22316604.
27. Hobbs J, Nikiforova MN, Fardo DW, Bortoluzzi S, Cieply K, Hamilton RL, Horbinski C. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol 2012, 36:1186-1193. 10.1097/PAS.0b013e3182518e12, 3393818, 22472960.
28. Idbaih A, Marie Y, Sanson M. NFKBIA deletion in glioblastomas. N Engl J Med 2011, 365:277. author reply 277-8.
29. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141-1149. 10.1038/ng.2734, 23917401.
30. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SRR, Zheng S, Chakravarty D, Sanborn JZZ, Berman SHH, Beroukhim R, Bernard B, Wu C-J, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WKK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DDD, Van Meir EG, Prados M, Sloan A, Black KLL, et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477. 10.1016/j.cell.2013.09.034, 24120142.
31. Wooten EC, Fults D, Duggirala R, Williams K, Kyritsis AP, Bondy ML, Levin VA, O'Connell P. A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro Oncol 1999, 1:169-176. 1920743, 11550311.
32. Hu J, Pang JC-S, Tong CY-K, Lau B, Yin X-L, Poon W-S, Jiang C-C, Zhou L-F, Ng H-K. High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours. Br J Cancer 2002, 87:218-224. 10.1038/sj.bjc.6600430, 2376105, 12107846.
33. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2011, 2:646-653. 3248209, 21896960.
34. Young KM, Bartlett PF, Coulson EJ. Neural progenitor number is regulated by nuclear factor-kappaB p65 and p50 subunit-dependent proliferation rather than cell survival. J Neurosci Res 2006, 83:39-49. 10.1002/jnr.20702, 16307445.
35. Widera D, Mikenberg I, Elvers M, Kaltschmidt C, Kaltschmidt B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappaB signaling. BMC Neurosci 2006, 7:64. 10.1186/1471-2202-7-64, 1586209, 16987412.
36. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt S-N, Borges I. Ruiz i Altaba A: NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010, 29:2659-2674. 10.1038/emboj.2010.137, 2928692, 20581802.
37. Torres J, Watt FM. Nanog maintains pluripotency of mouse embryonic stem cells by inhibiting NFkappaB and cooperating with Stat3. Nat Cell Biol 2008, 10:194-201. 10.1038/ncb1680, 18223644.
38. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L, Casafont I, Segura V, Robles EF, Suarez D, Garcia LF, Martinez-Climent JA, Fernandez-Luna JL. Blockade of the NFκB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene 2011, 30:3537-3548. 10.1038/onc.2011.74, 21423202.
39. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen P, Eskilsson E, Stieber D, Keunen O, Brekka N, Moen I, Nigro JM, Vintermyr OK, Lund-Johansen M, Niclou S, Mørk SJ, Enger PO, Bjerkvig R, Miletic H. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol 2013, 125:683-698. 10.1007/s00401-013-1101-1, 3631314, 23429996.
40. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21:2683-2710. 10.1101/gad.1596707, 17974913.
41. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, Patanè M, Maderna E, Pollo B, Comoglio PM, Finocchiaro G, Boccaccio C, Patane M. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 2012, 72:22738909.
42. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24:331-346. 10.1016/j.ccr.2013.08.001, 23993863.